KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Exchange Rate Effect (2016 - 2025)

Biomarin Pharmaceutical's Exchange Rate Effect history spans 12 years, with the latest figure at $1.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect fell 51.32% year-over-year to $1.2 million, compared with a TTM value of -$2.5 million through Dec 2025, down 152.19%, and an annual FY2025 reading of -$2.5 million, down 152.19% over the prior year.
  • Exchange Rate Effect for Q4 2025 was $1.2 million at Biomarin Pharmaceutical, up from $739000.0 in the prior quarter.
  • The five-year high for Exchange Rate Effect was $3.3 million in Q2 2024, with the low at -$3.6 million in Q4 2023.
  • Average Exchange Rate Effect over 5 years is $179600.0, with a median of $150000.0 recorded in 2022.
  • Biggest YoY gain for Exchange Rate Effect was 814.81% in 2023; the steepest drop was 5236.62% in 2023.
  • Tracing BMRN's Exchange Rate Effect over 5 years: stood at -$22000.0 in 2021, then soared by 422.73% to $71000.0 in 2022, then tumbled by 5236.62% to -$3.6 million in 2023, then surged by 168.66% to $2.5 million in 2024, then crashed by 51.32% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Exchange Rate Effect are $1.2 million (Q4 2025), $739000.0 (Q3 2025), and -$3.1 million (Q2 2025).